Skip to content
Medical Health Aged Care

General Use Item decision welcomed by private hospitals

Australian Private Hospitals Association (APHA) 2 mins read

Media Release

Wednesday 1 May 2024

 

General Use Item decision welcomed by private hospitals

The private hospital sector has welcomed Health Minister Mark Butler’s decision to retain General Use Items (GUIs) on the Prescribed List of Medical Devices and Human Tissue Products which he announced today.

Australian Private Hospitals Association (APHA) CEO Michael Roff said the GUIs were scheduled to be removed from the on 1 July this year, which would have added additional and unnecessary financial pressure on the sector.

“Removal would have been a little over eight weeks from now, which means guaranteed funding levels for these items would have disappeared.

Mr Roff said removing GUIs would have made some surgeries untenable for many private hospitals.

“Procedures like bariatric surgery, knee replacements, and cardiothoracic surgery would have been at risk in the private sector, potentially leading to increased demand on overstretched public hospitals.

“The health insurance sector had not been able to devise a sustainable funding model for GUIs, which would have left private hospitals managing increased costs at a time they could least afford it.

“Despite a range of proposals from different health insurance companies, none offered a viable alternative funding model with all of them shifting financial risk onto private hospitals. Potentially, this could have added $250 million in costs to the private hospital sector,” he said.

Health insurers have already achieved significant savings on these items as they have been subject to full public sector reference pricing. This has contributed to an industry-wide profit of $2 billion for health insurance companies.

“While private hospitals have been facing significant financial pressures, with services and in some cases entire facilities closing, health insurance companies have enjoyed a period of super profits.

“APHA has been advocating GUIs should remain on the PL for many years, we were successfully able to have removal deferred for 12 months last July when the timeframe for implementation was unreasonable. Now the Minister has recognised that pushing on with removing these items from the list would cause unnecessary additional financial stress to the private hospital sector.

“We are grateful the Minister has listened to our representations and reversed a decision that would have added to the financial pressure on private hospitals,” he said.

 

-ENDS-

Media contact: Frith Rayner, Director Communications and Marketing, 0413 971 999.


Contact details:

Frith Rayner

Director, Communications and Marketing

0413 971 999

Media

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.